Leap Therapeutics, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
LPTX Company Description
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
LPTX Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view LPTX Smart Score
Score Breakdown
LPTX Company Description
Show More
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. . Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of LPTX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by LPTX's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on LPTX's company Twitter account
WallStreetBets
Number of mentions of LPTX in WallStreetBets Daily Discussion
LPTX News
Recent insights relating to LPTX
CNBC Recommendations
Recent picks made for LPTX stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in LPTX
Corporate Flights
Flights by private jets registered to LPTX
Our Analysis